唑来膦酸治疗骨转移癌疼痛的临床观察  

Clinical study of zoledronic acid for pain control in bone metastatic cancer

作　　者：李园[1] 崔慧娟[1] 武晓勤[1] 程志强[1] 谭煌英[1] 

机构地区：[1]中日友好医院中医肿瘤科,北京100029

出　　处：《中国肿瘤临床与康复》2006年第6期571-574,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察唑来膦酸治疗恶性肿瘤骨转移导致疼痛的疗效及安全性。方法恶性肿瘤骨转移伴中重度疼痛患者38例,随机双盲分为A组(治疗组)20例唑来膦酸4mg溶于生理盐水50ml,静脉滴注(15min);安慰剂+生理盐水500ml,静脉滴注(4h);B组(对照组)18例安慰剂+生理盐水50ml,静脉滴注(15min);帕米膦酸二钠60mg+生理盐水500ml,静脉滴注(4h)。结果A组显效率85.0%,B组为83.4%,差异无显著性(P>0.05)。起效时间分别为5.2d与5.5d。结论唑来膦酸缓解恶性肿瘤骨转移所致疼痛有效,副作用小,患者可耐受,其有效性和安全性与帕米膦酸二钠相似。Objective To observe and evaluate the efficacy and safety of zoledronic acid in treatment of pain in patients with bone metastases. Methods Thirty-eight patients with bone metastatic tumor pain were randomly double-blind divided into two groups （ A and B）. Patients in group A （ the experimental group,20 cases） were treated with zoledronic acid 4 mg ＋0.9% NS 50 ml intravenous infusion in 15 minites and placebo ＋0.9% NS 500 ml intravenous infusion in 4 hours. Patients in group B （the control group, 18 cases） were treated with placebo ＋0.9% NS 50 ml intravenous infusion in 15 minites and pamidronate 60 mg ＋0.9% NS 500 ml intravenous infusion in 4 hours. Results The total response rate of inhibition of pain was 85.0% in the zoledronic acid group, and 83.4% in the control group,with no statistical difference between the two groups （ P 〉 0.05 ）. The time to effect was 5.2 days and 5.5 days respectively. Conclusion Zoledronic acid is effective in treatment of pain in patients with metastatic tumor of bone. It is safe and well tolerated, which is similar to pamidronate.

关 键 词：唑来膦酸 骨转移癌 疼痛 

分 类 号：R738[医药卫生—肿瘤]